CD8A and cancer: We have hypothesized of taking advantage of this physiological phenomenon to develop a novel therapeutic approach for solid cancer treatment that exploit the capability of activated monocytes to transfer the MHC-I/peptide antigens complexes (pMHC-I) to cancer cells, making them target of a “natural” cytotoxic response of CD8+ lymphocytes.